Qiagen's CEO discussed the company's focus on specific growth drivers, while Invitae's CEO talked about pandemic-related challenges in its genetic testing business.
The company posted Q2 revenues of $520.0 million, down 13 percent from $599.2 million in Q2 2019, but above analysts' average estimate of $496.9 million.
The GenomeWeb Index rose more than 2 percent in June, but the increase was subdued compared to the index's 9 percent climb in May and 18 percent hike in April.
Waters posted revenues of $464.9 million for the quarter as the SARS-CoV-2 pandemic drove a drop in sales globally, including a 45 percent decline in China.
Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.